ED Usage Tips

(ways to make things easier for your patients when referring them)

 

* Utilize CHOA App for ED/urgent care wait times

* Encourage patients to utilize MyChart to see labs

* If sending patient for a procedure, for ex: abscess drainage, fracture reduction keep them NPO

* ALWAYS call transfer center before referring a patient

* Hughes Spalding is different: no access to surgeons, no ICU, no 24 hour ultrasound, no MRI, minimal subspecialists-Hematology and the O’s (Opthalmology, Non-surgical Orthopedics, Oral Surgery)

* When referring a patient leave a cell phone number to contact you and update your colleagues on patients being referred to the ED

* Labs and X-rays can be done at the hospital as outpatients with an order from you – the patient doesn’t have to come via the ED unless you also want them seen by an ED physician.

* Respiratory viral panel testing is generally not indicated for previously healthy children in whom treatment for influenza is not necessary (or can be done on clinical grounds)

To Tamiflu or Not to Tamiflu?

 

shpic

Sherita Holmes, MD sherita.holmes@emory.edu

Every year we expect a flu epidemic which usually starts in the fall and lasts until spring (as early as October and last until late May).  According to the most recent CDC Weekly U.S. Influenza Surveillance Report (week 8 – February 25th), flu activity remains elevated in the United States; although it appears to be downtrending.1
We know that in a majority of patients; the flu manifests as a nuisance that causes our patients to have high fevers with self-limited respiratory symptoms, fatigue, and myalgias. However, we also know that in the very young (age < 2 years) or very old (age > 65 years) as well as those with underlying medical conditions (i.e. asthma, immunosuppression, diabetes, heart disease) [see Table 1]; the flu can be fatal. This flu season there have been 40 pediatric deaths reported thus far [Figure 1].1 This underscores the importance of prevention and why it is critical that we encourage flu vaccination, especially in these high risk groups.

 

While vaccination is important in preventing influenza, we can use antiviral medications to shorten the length of illness (by 1-2 days), reduce complications such as pneumonia, and lessen severity.2 Antiviral medications should be started as soon as possible – ideally within the first 48 hours of illness – for any patient with suspected or confirmed influenza who: has severe, complicated, or progressive illness; is in a high risk group; or is hospitalized.3 Consider chemoprophylaxis in patients in high risk groups with known exposure to influenza.

 

There are two classes of antivirals for influenza: neuraminidase inhibitors (oseltamivir, zanamivir) and adamantanes (amantadine, rimantadine). The adamantanes are not effective against influenza B and there are high levels of resistance against the current influenza A viruses. For 2016-2017 flu season, the CDC only recommends using the neuraminidase class of antivirals. Oseltamivir (Tamiflu) is available in pill or liquid form, while zanamivir (Relenza) only available in inhaled form. Please refer to Tables 2 and 3 for further information regarding antiviral medication age designations, contraindications, adverse effects, and dosages.3,4

 

In the battle against influenza, we must do our best to not only identify the appropriate patients that would benefit from antiviral medications, but most importantly to encourage all patients and their loved ones to get vaccinated.

 

 

 

 

CDC https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm

Table 3 Harper et al. https://doi.org/10.1086/598513

 

 

 

 

 

References:

 

  1. CDC Weekly U.S. Influenza Surveillance Report

https://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html

 

  1. Campbell, Angela. CDC Expert Commentary 2016-2017 Influenza Antiviral Recommendations

http://www.medscape.com/partners/cdc/public/cdc-commentary

 

  1. Centers for Disease Control (CDC) and Prevention 2016-2017 Flu Season

https://www.cdc.gov/flu/about/season/current.htm

 

  1. Harper, S.A., Bradley, J.S., Englund, J.A., et al. Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America

https://doi.org/10.1086/598513

Pediatric Appendicitis Practice Guidelines

Reena Blanco, MD
rnarwan@emory.edu

Alesia Fleming, MD, MPH
aflemi2@emory.edu

 

Acute appendicitis is the most common, non-traumatic surgical emergency encountered in children. Early identification can lead to timely removal preventing perforation and its complications.  Abdominal pain is a common symptom in the emergency department.  To help differentiate the surgical from medical emergencies, CHOA emergency medicine, surgery and radiology teams collaborated to develop the suspected appendicitis clinical guideline.

The broad goals of the team were to:

  • Identify children with the highest risk of appendicitis
  • decrease utilization of abdominal CT to diagnose appendicitis
  • Increase utilization of the Pediatric Appendicitis Score (PAS).
  • Streamline and standardize clinical evaluation
  • Decrease time to diagnosis and definitive care

 

The guideline was implemented in 2013 using the PAS as a common language tool to better communicate across services.  Patients 5 years and older with abdominal pain for less than 72 hours** suspected of having appendicitis are evaluated according to the pathway with screening labs, given an initial IV fluid bolus and pain medication.  After this, the PAS score is calculated and used to further guide care and communicate across services for next steps.

Patients with a PAS of 0-4 have a low suspicion for appendicitis. The physician should consider other diagnoses. There is always a risk that the patient may develop further symptoms as disease progresses therefore if discharged home, these patients need to be seen by their PCP within 24 hours for re-evaluation.

A PAS of 5-7 is equivocal for appendicitis and diagnostic imaging or surgical consult is warranted.  The guideline promotes US as the exam of choice for initial evaluation.  Ultrasound has a sensitivity is 98% and specificity is 92% in identifying appendicitis in those where the appendix was clearly seen. In addition to eliminating exposure to ionizing radiation ultrasound can evaluate female patients for ovarian torsion which is part of the differential of appendicitis.  The exact correlations between radiation exposure and cancer in children is not known, and utilizing alternative imaging modalities such as ultrasound limit exposure to ionizing radiation.

If the patient has a PAS >8 there is a high suspicion for appendicitis, imaging is not required, and surgery should be immediately consulted.

The guideline does not represent a professional care standard and physicians will need to be prudent in determining most appropriate care, but it does offer an approach to abdominal pain that should help with efficiency of care and ultimate outcome of our patients.

 

**exclusions outlined in clinical practice guidelines on md.choa.org under

clinical excellence->clinical practice guidelines

 

 

Streptococcus Pharyngitis Q and A-Ask the Expert?

By Chris Van Beneden, MD MPH. GetSmart@cdc.gov

By Chris Van Beneden, MD MPH. GetSmart@cdc.gov

By Katherine Fleming-Dutra, MD GetSmart@cdc.gov

By Katherine Fleming-Dutra, MD GetSmart@cdc.gov

By Craig Shapiro, MD cshapi2@emory.edu

By Craig Shapiro, MD cshapi2@emory.edu

 

1. What are the different types of diseases that Group A strep causes?

Streptococcus pyogenes are gram-positive cocci that grow in chains. They are β -hemolytic, meaning that they exhibit a clear zone of hemolysis when grown on blood agar plates. They belong to group A in the Lancefield classification system for β-hemolytic Streptococcus, and thus are also called group A Streptococcus. Group A Streptococcus can cause a variety of infections, the most common of which is streptococcal pharyngitis or strep throat. Group A Streptococcus can also cause scarlet fever, skin infections like impetigo and cellulitis, non-suppurative complications of streptococcal infections such as acute rheumatic fever and post-streptococcal glomerulonephritis, and invasive diseases such as pneumonia, septic arthritis, septicemia, meningitis, necrotizing fasciitis, streptococcal toxic shock syndrome, and musculoskeletal and surgical wound infections.

2. What causes the rash of scarlet fever?

Scarlet fever, or scarlatina, is a strep infection that occurs with a characteristic scarlatiniform rash. The characteristic rash is red with fine papules (“sandpaper”), appearing initially on the trunk and spreading peripherally over hours to days to cover almost the entire body. Most often scarlet fever occurs with streptococcal pharyngitis but it can occur with streptococcal wound infections or impetigo. It is caused by a particular strain of group A Streptococcus that produces a pyrogenic exotoxin, which leads to the rash.

3. Should we treat patients just based on the scarlatiniform rash?

Because the differential diagnosis of scarlet fever includes viral pharyngitis with a viral exanthema and other mucocutaneous syndromes such as Kawasaki Disease and Stevens-Johnson syndrome (SJS), the diagnosis of scarlet fever should be confirmed with a rapid antigen detection test (i.e. rapid strep test) performed on a throat swab or throat culture prior to antibiotic treatment.

4. If a patient has a positive strep test, do we have to treat?

CDC encourages clinicians to follow the Infectious Diseases Society of America (IDSA) 2012 Clinical Practice Guidelines for the Diagnosis and Management of Group A Streptococcal Pharyngitis. These are national, evidence-based recommendations regarding how to diagnose and treat streptococcal pharyngitis.

Streptococcal pharyngitis is usually self-limited, even if not treated with antibiotics. However, IDSA recommends treatment with antibiotics for patients with streptococcal pharyngitis because it speeds recovery, limits transmission of group A Streptococcus to others, and most importantly, decreases the risk of acute rheumatic fever and suppurative complications (e.g., peritonsillar abscess, mastoiditis).

It is important to emphasize that IDSA recommends treatment for patients with symptomatic streptococcal pharyngitis that has been confirmed to be due to group A Streptococcus using a positive rapid antigen detection test (also called a rapid strep test) or throat culture. This is because asymptomatic colonization with group A Streptococcus is very common. In the winter, as many as 20% (1 in 5) of children can be asymptomatically colonized in the oropharynx with group A Streptococcus and will test positive by rapid strep test or throat culture. However, children with asymptomatic colonization typically do not need antibiotic treatment; these children do not have symptoms, are much less likely to transmit group A Streptococcus to others, and are very unlikely to develop suppurative or nonsuppurative complications, such as acute rheumatic fever.

A rapid strep test or throat culture should only be performed in children who have signs and symptoms of streptococcal pharyngitis. Because colonization is common, testing children who do not have signs and symptoms of strep throat leads to many false positives and unnecessary antibiotic use. IDSA states that patients with clear viral symptoms—including cough, runny nose, hoarseness, oral ulcers, conjunctivitis—do not need to be tested for group A Streptococcus because these are symptoms of viral pharyngitis.

Antibiotics have risks too—including allergies, side effects, and promotion of antibiotic resistance. Correctly selecting the patients who need a strep test can help us protect our patients from avoidable adverse drug events and antibiotic resistance.

5. Some children keep getting recurrent streptococcal pharyngitis. Why is that?

It is not uncommon to see a child several times a year with sore throat and positive test results for group A Streptococcus. Many children who appear to have recurrent streptococcal pharyngitis actually have recurrent episodes of viral pharyngitis and are asymptomatically colonized with group A Streptococcus. They test positive for group A Streptococcus because they are colonized. Repeated antibiotic treatment in these children is unnecessary because they are less likely to transmit group A Streptococcus to others and are very unlikely to develop complications. However, identifying carriers can be difficult. How to determine whether someone is a carrier is addressed in the Infectious Diseases Society of America guidelines and the Red Book.

6. What are the signs/symptoms of group A Streptococcus infection?

The main signs and symptoms of streptococcal pharyngitis are sore throat with a sudden onset, pain with swallowing, and fever. Streptococcal pharyngitis also commonly presents with patchy exudates on the tonsils and anterior cervical lymphadenopathy. Streptococcal pharyngitis may include headache, abdominal pain and vomiting, but these symptoms occur in the presence of sore throat symptoms.

Streptococcal pharyngitis does not cause cough, runny nose, hoarseness, oral ulcers or conjunctivitis. These are symptoms that more commonly occur with viral pharyngitis, and therefore neither strep testing nor antibiotics are needed for patients with these symptoms.

7. What ages commonly get strep pharyngitis?

Streptococcal pharyngitis is most common among children 5 to 15 years of age, but it can occur in adults. It is very rare in children younger than 3 years of age, as streptococcal disease in children less than 3 years of age rarely manifests as pharyngitis. Instead, young children with group A Streptococcus infection may get a mucopurulent rhinitis associated with fever, irritability, and poor appetite.

8. Which ages groups should be tested for strep pharyngitis?

Streptococcal pharyngitis is most common among children 5 through 15 years of age. Because children less than 3 years of age rarely get streptococcal pharyngitis and acute rheumatic fever is very rare in children less than 3 years, IDSA guidelines recommend against routinely testing children less than 3 years of age for streptococcal pharyngitis, as this may lead to false-positive tests and unnecessary antibiotic use. In select symptomatic children less than 3 years of age who have other risk factors for GAS pharyngitis, such as children who have an older sibling with confirmed streptococcal pharyngitis, IDSA guidelines state that testing can be considered.

9. What is the risk of scarlet fever in adults?

Scarlet fever can occur in adults if infected with the strain of group A Streptococcus that produces a pyrogenic exotoxin. However, scarlet fever is most common in children 5 to 15 years of age.

10. Is there any benefit to treating patients <2 years old?

The vast majority of children less than 3 years of age should not be tested for streptococcal pharyngitis, as this can lead to false-positive tests and unnecessary antibiotic use. In select children less than 3 years of age, such as symptomatic children who have an older sibling with confirmed streptococcal pharyngitis, IDSA guidelines state that testing can be considered.

11. When do you treat asymptomatic siblings of a child with a positive strep test? Is there a lower age limit for that? (I.e. would you treat a 6 month-old who’s 4 yea- old sibling has strep?)

IDSA guidelines specifically recommend against streptococcal testing or treating asymptomatic household contacts of patients with streptococcal pharyngitis. One-third of household contacts of children with streptococcal pharyngitis will become symptomatic, in which case testing and treatment is indicated. However, studies have shown that treating asymptomatic household contacts with penicillin is not effective at preventing them from later developing symptomatic streptococcal pharyngitis. Treating asymptomatic household contacts needlessly exposes them to the risks of antibiotics without benefiting them.

12. Is there a website/poster that is available from the CDC that we can share with our colleagues or patient families?

For more information about group A Streptococcus, please visit: http://www.cdc.gov/groupastrep/diseases-public/index.html

For more information about appropriate antibiotic use and the Get Smart: Know When Antibiotics Work Program, please visit: http://www.cdc.gov/getsmart/ Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86–102.

Committee on Infectious Diseases. Group A streptococcal infections. In Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. 30th ed. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village (IL): American Academy of Pediatrics; 2015:732–44.

Questions answered by: Katherine Fleming-Dutra, MD, Craig Shapiro, MD, and Chris Van Beneden, MD MPH.

Dr. Fleming-Dutra is a pediatric emergency physician with the Get Smart: Know When Antibiotics Program in the Office of Antibiotic Stewardship at the Centers for Disease Control and Prevention (CDC). Dr. Shapiro is pediatric infectious diseases physician and director of the Antibiotic Stewardship Program at Children’s Healthcare of Atlanta. Dr. Van Beneden is a medical epidemiologist and expert on group A Streptococcus in the Respiratory Diseases Branch in the Division of Bacterial Diseases at CDC.

CHOA Heavy Menstrual Bleeding Guideline

By Amy Pattishall apattis@emory.edu

By Amy Pattishall
apattis@emory.edu

 

Heavy Menstrual Bleeding Guideline

Children’s Healthcare of Atlanta Emergency Department (ED) implemented one of its newest guidelines, for Heavy Menstrual Bleeding (HMB), in August 2016. This guideline represents a collaboration of several specialties, including Pediatric Emergency Medicine, Urgent Care, Hematology, Adolescent Medicine and Gynecology, with the goals of:

* Establishing a uniform process for evaluation and management of adolescents with HMB

* Reducing repeat visits to the ED for the same concern

* Expediting diagnosis of congenital bleeding disorders

* Improving the quality of life for adolescents experiencing HMB

* Providing improved opportunities for adolescent and gynecology follow up care

Why is such a guideline necessary?

Many adolescents with HMB present to the ED for evaluation, whether they are symptomatic or not. Evidence shows that patients presenting with HMB receive variable workups, potentially delaying diagnosis of bleeding disorders. This guideline helps to ensure that all adolescents at risk for a bleeding disorder receive appropriate laboratory evaluation and follow up with hematology or gynecology. HMB can also cause chronic iron deficiency anemia and affect adolescents’ quality of life. We hope the guideline will help improve patients’ quality of life by standardizing treatment for HMB.

Which patients are included in the guideline?

Any menstruating female with concern for HMB meets inclusion criteria. Patients with previously diagnosed bleeding disorders are excluded. The guideline incorporates an evidence-based screening tool to determine if laboratory workup for a congenital bleeding disorder is necessary, which is considered positive if the patient answers “yes” to any of the screening questions.

Screening Questions (Adapted from Claire Phillip Screening tool; AMJOG 2011):

1. On average does your period last 7 or more days?

2. Do you experience “flooding” or overflow bleeding through your tampon or pad?

3. Do you need to change your pad or tampon more than every 1-2 hours at times during your period?

4. Have you ever been treated (PO iron, IV iron, blood transfusions) for iron deficiency anemia in the past?

5. Do you have a family history of a bleeding disorder?

6. Have you had excessive bleeding with a dental extraction or dental surgery?

7. Have you had excessive bleeding with a miscarriage or following delivery of a child?

How do providers use the guideline?

The guideline stratifies patients based on severity of anemia and symptoms to help determine need for admission and IV versus oral medications. Recommendations on hormone and adjunct treatment (iron, anti-emetics, stool softeners) are included, as well as contact numbers for follow up at Emory Fellows’ Family Planning/Gynecology clinic, the Adolescent Medicine clinic at Hughes Spalding, and the CHOA Hematology clinic.

The HMB guideline, along with the full evidence summary, can be accessed on the CHOA Physician Portal: md.choa.org.

For Bronchiolitis, Less is More

 

By Shabnam Jain sjain@emory.edu

By Shabnam Jain
sjain@emory.edu

 

Bronchiolitis is a self-limited, viral lower respiratory tract infection that affects infants and young children.  It is the most common cause of hospital admission in infants in the US. In 2014, the American Academy of Pediatrics published a clinical practice guideline (CPG) entitled The Diagnosis, Management, and Prevention of Bronchiolitis.(1)   The CPG excludes infants under 1 month of age, those with hemodynamically significant cardiac disease, significant pulmonary disease, or major chronic conditions. Based on this CPG, in 2015 the AAP Section on Emergency Medicine developed a clinical algorithm for bronchiolitis in the ED setting, addressing some newer therapies that can be considered in severe or undifferentiated presentations. (2) It also offers criteria for which patients can be discharged from the ED and may be helpful for primary care providers in making decisions on whom to refer to the ED. Children’s Healthcare of Atlanta has its own guidelines as well. (3)  These resources may be useful for the generally healthy infant with bronchiolitis with the following recommendations applicable to pediatric outpatient practice:

 

  1. Diagnosis and severity assessment is made on the basis of history and physical exam and assessment of risk factors. Routine chest X-rays and RSV testing are not recommended. 
  2. Management: Albuterol may improve respiratory score (subjective), but has no effect on clinical course, disease resolution, admission, or length of stay.  It does however, increase adverse effects (tremors, tachycardia) which outweighs any small potential benefits. Albuterol is not recommended for routine use in bronchiolitis.  Furthermore, there is no benefit from routine use of epinephrine in inpatients or outpatient settings. Epinephrine may be used as a rescue agent in severe disease.  Finally, steroids have no role in the management of bronchiolitis.
  3. Oxygen and Pulse oximetry: There is poor correlation between respiratory distress and oxygen sats.  Transient hypoxemia is common in bronchiolitis; pulse oximetry has been associated with perceived need for admission and is a primary determinant of inpatient LOS. Providers may choose not to give O2 if sats >90%  and may choose not to use continuous pulse oximetry
  4. Antibiotics are not indicated unless there is a concomitant bacterial infection.

 

Patients who meet the following are generally considered appropriate for discharge home:

  • Room air sats consistently ≥ 90% while awake or >88% while asleep
  • Able to handle secretions or need bulb suctioning only
  • Adequate activity & hydration
  • Parents able to follow-up with PCP within 48 hours or access emergency care if needed

 

For the previously healthy, mild to moderate bronchiolitis patient, the current strategy is: Don’t just do something, stand there!

 

  1. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502 – October 01, 2015.    http://pediatrics.aappublications.org/content/134/5/e1474
  2. Jain S, Stack A, Baskin M, et al. Clinical Algorithm for Bronchiolitis in the Emergency Department Setting    http://www2.aap.org/sections/pem/PDF/AAPSOEMCOQTBronchiolitisGuideline.pdf
  3. Children’s Healthcare of Atlanta (Clinical Excellence page). https://md.choa.org/clinical-excellence/clinical-practice-guidelines/bronchiolitis

Fever, Viral Symptoms and Testing for Viruses

 

Burgerpic

by Becky Burger, MD

BeckyBurger@emory.edu

As we approach respiratory viral season, we wanted to share our emergency department guideline for performing viral testing via the Respiratory Viral Panel (RVP) test. The RVP is a nasal swab test that detects viruses including influenza, RSV, and several other viruses. The turnaround time for the RVP result is between one and three hours. We have found that these tests sometimes delay disposition and often don’t change management of the patient in the ED. Our quality improvement committee developed the guidance below to optimize RVP testing in the ED.   Please note that we do not perform the new molecular rapid influenza test in the emergency departments at Children’s.

For ED patients being discharged home:

  • RVP usually not indicatedHealthy patients with viral symptoms.   This is because of the following reasons:
  • Prolonged positivity of RVPs from prior illnesses (unrelated to current symptoms)
  • Multiple positives
  • False sense of security
  • Management can usually be based on clinical grounds (e.g. treating influenza in high-flu season)
  • RVP may be done on a case-by-case basisPatients with underlying chronic medical condition, or patients in the age range 4-8 week old with fever etc. where a positive test may change management– in such instances, RVP is helpful only if we wait for result of the test for further decision making such as extent of work up, admission vs. discharge, etc.

For ED patients who require admission:

  • RVP indicatedImmunocompromised patients (such as transplants and certain chronic medical conditions) and other patients at high risk for complications of infection.
  • RVP usually not necessaryImmunocompetent patients (with or without chronic medical problems) – inpatient team may choose to order it themselves if desired.
  • All inpatient rooms at Children’s are private rooms so we don’t need to use RVPs for cohorting purposes.  Also, all respiratory illness patients need appropriate infection control precautions regardless of the result of the RVP.

We do not recommend referral to the emergency department just for RVP testing in well appearing children who have symptoms consistent with viral respiratory infection. For patients with symptoms concerning for influenza who are at higher risk (based on age, severity, or underlying medical conditions), treatment with antiviral medications can be started without the need for lab confirmation of influenza, (particularly during high flu prevalence).

If you have any questions about RVP testing, feel free to contact: Becky Burger, MD, BeckyBurger@emory.edu